BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rückert A, Glimm H, Lübbert M, Grüllich C. Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up. Lupus 2008;17:757-60. [PMID: 18625656 DOI: 10.1177/0961203307087876] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Jaime-Pérez JC, Aguilar-Calderón PE, Salazar-Cavazos L, Gómez-Almaguer D. Evans syndrome: clinical perspectives, biological insights and treatment modalities. J Blood Med 2018;9:171-84. [PMID: 30349415 DOI: 10.2147/JBM.S176144] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
2 Lefkou E, Nelson-Piercy C, Hunt BJ. Evans' syndrome in pregnancy: a systematic literature review and two new cases. Eur J Obstet Gynecol Reprod Biol 2010;149:10-7. [PMID: 20031296 DOI: 10.1016/j.ejogrb.2009.11.022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
3 Tkachenko O, Lapin S, Maslyansky A, Myachikova V, Mikhailova L, Gilburd B. Relapsing Evans syndrome and systemic lupus erythematosus with antiphospholipid syndrome treated with Bortezomib in combination with plasma exchange. Clinical Immunology 2019;199:44-6. [DOI: 10.1016/j.clim.2018.12.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
4 Khattri S, Zandman-goddard G, Peeva E. B-cell directed therapies in antiphospholipid antibody syndrome — New directions based on murine and human data. Autoimmunity Reviews 2012;11:717-22. [DOI: 10.1016/j.autrev.2011.12.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
5 Bianco C, Coluccio E, Prati D, Valenti L. Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders. J Clin Med 2021;10:423. [PMID: 33499290 DOI: 10.3390/jcm10030423] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Emmi G, Silvestri E, Squatrito D, Ciucciarelli L, Cameli AM, Denas G, D'Elios MM, Pengo V, Emmi L, Prisco D. An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditions. ScientificWorldJournal 2014;2014:341342. [PMID: 25374937 DOI: 10.1155/2014/341342] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
7 Pons I, Espinosa G, Cervera R. [Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: analysis of 24 cases from the bibliography review]. Med Clin (Barc) 2015;144:97-104. [PMID: 24698717 DOI: 10.1016/j.medcli.2014.01.034] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
8 Mormile I, Granata F, Punziano A, de Paulis A, Rossi FW. Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It? Biomedicines 2021;9:132. [PMID: 33535377 DOI: 10.3390/biomedicines9020132] [Reference Citation Analysis]
9 Dobrowolski C, Erkan D. Treatment of antiphospholipid syndrome beyond anticoagulation. Clin Immunol 2019;206:53-62. [PMID: 29510235 DOI: 10.1016/j.clim.2018.03.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
10 Barcellini W, Zanella A. Rituximab therapy for autoimmune haematological diseases. Eur J Intern Med. 2011;22:220-229. [PMID: 21570637 DOI: 10.1016/j.ejim.2010.12.016] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 4.2] [Reference Citation Analysis]
11 Kumar D, Roubey RAS. Use of Rituximab in the Antiphospholipid Syndrome. Curr Rheumatol Rep 2010;12:40-4. [DOI: 10.1007/s11926-009-0074-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
12 Comarmond C, Cacoub P. Antiphospholipid syndrome: From pathogenesis to novel immunomodulatory therapies. Autoimmunity Reviews 2013;12:752-7. [DOI: 10.1016/j.autrev.2012.12.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
13 La Cava A. Targeting B cells with biologics in systemic lupus erythematosus. Expert Opin Biol Ther 2010;10:1555-61. [PMID: 20919800 DOI: 10.1517/14712598.2010.524923] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
14 Arkfeld DG, Weitz IC. Immune thrombocytopenia in patients with connective tissue disorders and the antiphospholipid antibody syndrome. Hematol Oncol Clin North Am. 2009;23:1239-1249. [PMID: 19932431 DOI: 10.1016/j.hoc.2009.08.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
15 Falgarone G, Dhote R, Boissier M. B-cell targeted treatments for lupus: The journey counts as much as the destination. Joint Bone Spine 2012;79:437-40. [DOI: 10.1016/j.jbspin.2012.02.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Jarasvaraparn C, Imran H, Siddiqui A, Wilson F, Gremse DA. Association of autoimmune hepatitis type 1 in a child with Evans syndrome. World J Hepatol 2017;9:1008-12. [PMID: 28878866 DOI: 10.4254/wjh.v9.i23.1008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Mantadakis E, Farmaki E. Natural History, Pathogenesis, and Treatment of Evans Syndrome in Children. J Pediatr Hematol Oncol 2017;39:413-9. [PMID: 28654461 DOI: 10.1097/MPH.0000000000000897] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
18 Gonzalez-Nieto JA, Martin-Suarez I, Quattrino S, Ortiz-Lopez E, Muñoz-Beamud FR, Colchero-Fernández J, Alcoucer-Diaz MR. The efficacy of romiplostim in the treatment of severe thrombocytopenia associated to Evans syndrome refractory to rituximab. Lupus 2011;20:1321-3. [PMID: 21719526 DOI: 10.1177/0961203311404913] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
19 Greaves M. Pathogenesis and management of antiphospholipid syndrome. Thrombosis Research 2009;123:S4-9. [DOI: 10.1016/s0049-3848(09)70002-7] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]